About Morepen Laboratories Ltd
Morepen Laboratories is in the business of manufacturing, producing, developing, marketing and distribution of a wide range of Active Pharmaceutical Ingredients (APIs), branded and generic formulations, Over the Counter (OTC) products and the Home Health products.
Founded
1984
CEO
Sushil Suri
Employees
3,125
HQ
Gurgaon, India
Finished Products
1API & Intermediates
₹2,698.10Cr2Home Health
₹1,179.21Cr3Formulation
₹244.13Cr4Formulations - Others - Traded
₹152.80Cr5Formulations - traded
₹92.96Cr6Home Health - Traded
₹44.65Cr7Export Incentives
₹15.69Cr1–7 of 9
Raw Materials
1API & Intermediates
₹1,694.33Cr2Home Health
₹766.66Cr3Formulations
₹202.91Cr4Formulations purchased
₹75.71Cr5Home health Purchased
₹72.82Cr6Formulations - Others - Traded
₹35.72Cr7Formulations-Purchased
₹3.48CrAbout Morepen Laboratories Ltd
Morepen Laboratories is in the business of manufacturing, producing, developing, marketing and distribution of a wide range of Active Pharmaceutical Ingredients (APIs), branded and generic formulations, Over the Counter (OTC) products and the Home Health products.
Founded:1984
CEO:Sushil Suri
Employees:3,125
HQ:Gurgaon, India
Finished Products
1API & Intermediates
₹2,698.10Cr2Home Health
₹1,179.21Cr3Formulation
₹244.13Cr4Formulations - Others - Traded
₹152.80Cr5Formulations - traded
₹92.96Cr6Home Health - Traded
₹44.65Cr7Export Incentives
₹15.69Cr1–7 of 9
Raw Materials
1API & Intermediates
₹1,694.33Cr2Home Health
₹766.66Cr3Formulations
₹202.91Cr4Formulations purchased
₹75.71Cr5Home health Purchased
₹72.82Cr6Formulations - Others - Traded
₹35.72Cr7Formulations-Purchased
₹3.48CrPrice Performance & Market EventsPrice Performance
Loading chart data…
Key Metrics
Trading & valuation snapshot
52W High
₹114
52W Low
₹33
Volume36.39M
Avg VolumeN/A
Beta1.52
Dividend Yield0.18%
Key Financial Ratios
Profitability, leverage & efficiency at a glance
P/E Ratio
43.93x
Valuation
P/B Ratio
4.96x
Valuation
EPS
₹2.57
Valuation
Dividend Yield
0.18%
Valuation
ROE
5.96%
Profitability
ROCE
7.58%
Profitability
Revenue by Segment
Contribution & growth by business line
PharmaceuticalsRevenue split N/A
Geographical Revenue Split
Domestic vs international exposure
Domestic
60.6%
International
39.4%
India60.6%
Rest of World32.7%
USA6.7%
Strategic Relations
Collaborations, joint ventures & subsidiaries
T
Techquim Etablissment
Switzerland
0.00% stakeK
Kaneka Corporation
Japan
0.00% stakeForensic Metrics
Financial health & earnings-quality indicators
Revenue Quality
N/A
Days Sales Outstanding
Leverage
0.17x
Debt-to-Equity
Earnings Quality
N/A
Cash Conversion Ratio
Efficiency
N/A
Asset Turnover
Earnings Quality
N/A
Accruals Ratio
Profitability
N/A
Gross Margin
Growth
8.5%
Sales Growth
These metrics are derived from available financial disclosures and market data. Use them together with company filings and qualitative analysis before making decisions.